Table 2. Targeted therapy trial for metastatic gastric adenocarcinoma.
| Study | Number | Target | Treatment | Survival | HR
(95% CI) |
Reference |
|---|---|---|---|---|---|---|
| First-line setting | ||||||
| ToGA | n = 298
n = 296 |
HER2 | Trastuzumab + XP
Placebo + XP |
mOS: 13.8 months
mOS: 11.1 months |
0.74
(0.60–0.91) |
34 |
| TRIO-013/LOGiC | n = 249
n = 238 |
HER2/EGFR | Lapatinib + CapeOx
Placebo + CapeOx |
mOS: 12.2 months
mOS: 10.5 months |
0.91
(0.73–1.12) |
59 |
| EXPAND | n = 455
n = 449 |
EGFR | Cetuximab + XP
Placebo + XP |
mOS: 9.4 months
mOS: 10.7 months |
1.00
(0.87–1.17) |
61 |
| REAL3 | n = 278
n = 275 |
EGFR | Panitumumab + EOC
Placebo + EOC |
mOS: 8.8 months
mOS: 11.3 months |
1.37
(1.07–1.76) |
62 |
| AVAGAST | n = 387
n = 387 |
VEGF | Bevacizumab + FP
Placebo + FP |
mOS: 12.1 months
mOS: 10.1 months |
0.87
(0.73–1.03) |
64 |
| RAINFALL | n = 326
n = 319 |
VEGFR | Ramucirumab + Cape/Cis
Placebo + Cape/Cis |
mOS: 11.2 months
mOS: 10.7 months |
0.68
(0.80–1.16) |
63 |
| RILOMET-1 | n = 304
n = 305 |
MET | Rilotumumab + ECX
Placebo + ECX |
mOS: 8.8 months
mOS: 10.7 months |
1.34
(1.10–1.63) |
65 |
| METGastric | n = 279
n = 283 |
MET | Onartuzumab + FOLFOX
Placebo + FOLFOX |
mOS: 11.0 months
mOS: 11.3 months |
0.82
(0.59–1.15) |
66 |
| Cohen et al. | n = 60
n = 63 |
Hedgehog
pathway |
Vismodegib + FOLFOX
Placebo + FOLFOX6 |
mOS: 11.5 months
mOS: 14.9 months |
- | 74 |
| FAST | n =84
n =77 |
Claudin18.2 | IMAB362 + EOX
Placebo + EOX |
mOS: 13.2 months
mOS: 8.4 months |
0.51
(0.36–0.73) |
78 |
| Beyond second-line setting | ||||||
| REGARD | n = 238
n = 117 |
VEGFR | Ramucirumab
Placebo |
mOS: 5.2 months
mOS: 3.8 months |
0.78
(0.60–0.99) |
46 |
| RAINBOW | n = 330
n = 335 |
VEGFR | Ramucirumab + paclitaxel
Placebo + paclitaxel |
mOS: 9.6 months
mOS: 7.4 months |
0.81
(0.68–0.96) |
45 |
| GATSBY | n = 228
n = 117 |
HER2 | Trastuzumab emtansine
Taxane |
mOS: 7.9 months
mOS: 8.6 months |
1.15
(0.87–1.51) |
58 |
| TyTAN | n = 132
n = 129 |
HER2/EGFR | Lapatinib + paclitaxel
Placebo + paclitaxel |
mOS: 11.0 months
mOS: 8.9 months |
0.84
(0.64–1.11) |
60 |
| GRANITE-1 | n = 439
n = 217 |
mTOR | Everolimus
Placebo |
mOS: 5.9 months
mOS: 4.3 months |
0.90
(0.75–1.08) |
67 |
| RADPAC | n = 150
n = 150 |
mTOR | Everolimus + paclitaxel
Placebo + paclitaxel |
mOS: 6.1 months
mOS: 5.1 months |
0.92
- |
68 |
| SHINE | n = 41
n = 30 |
FGFR | AZD4547
paclitaxel |
mOS: 5.5 months
mOS: 6.6 months |
1.31
(0.89–1.95) a |
69 |
| GOLD | n = 263
n = 262 |
PARP | Olaparib + paclitaxel
Placebo + paclitaxel |
mOS: 8.8 months
mOS: 6.9 months |
0.79
(0.63–1.00) |
72 |
a80% confidence interval. Cape/Cis, capecitabine and cisplatin; CapeOx, capecitabine and oxaliplatin; CI, confidence interval; ECX, epirubicin, cisplatin, and capecitabine; EGFR, epidermal growth factor receptor; EOC/EOX, epirubicin, oxaliplatin, and capecitabine; FGFR, fibroblast growth factor receptor; FOLFOX, leucovorin, 5-fluorouracil, and oxaliplatin; FP, cisplatin and 5-fluorouracil; HER2, human epidermal growth factor receptor 2; HR, hazard rate; MET, mesenchymal–epithelial transition; mOS, median overall survival; mTOR, mammalian target of rapamycin; PARP, poly (ADP-ribose) polymerase; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor; XP, cisplatin and capecitabine.